• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ICER's Revised Value Assessment Framework for 2017-2019: A Critique.

作者信息

Neumann Peter J, Cohen Joshua T

机构信息

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, #063, 800 Washington St., Boston, MA, 02111, USA.

出版信息

Pharmacoeconomics. 2017 Oct;35(10):977-980. doi: 10.1007/s40273-017-0560-y.

DOI:10.1007/s40273-017-0560-y
PMID:28791663
Abstract
摘要

相似文献

1
ICER's Revised Value Assessment Framework for 2017-2019: A Critique.ICER 2017 - 2019年修订后的价值评估框架：评论
Pharmacoeconomics. 2017 Oct;35(10):977-980. doi: 10.1007/s40273-017-0560-y.
2
Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?临床与经济评论学会是否会根据行业意见修改其研究结果？
Value Health. 2019 Dec;22(12):1396-1401. doi: 10.1016/j.jval.2019.08.003. Epub 2019 Oct 7.
3
HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications.美国卫生技术评估与经济学：评估趋势、确定与推荐意见相关因素并理解其影响的 ICER 报告系统评价
J Manag Care Spec Pharm. 2020 Dec;26(12):1548-1557. doi: 10.18553/jmcp.2020.26.12.1548.
4
NICE and new: appraising innovation.新颖与卓越：评估创新
BMJ. 2010 Jan 5;340:b5493. doi: 10.1136/bmj.b5493.
5
New technologies, critical care, and economic realities.新技术、重症监护与经济现实。
Crit Care Med. 1993 Nov;21(11):1777-80. doi: 10.1097/00003246-199311000-00030.
6
Challenges with Forecasting Budget Impact: A Case Study of Six ICER Reports.预测预算影响面临的挑战：六项 ICER 报告案例研究。
Value Health. 2019 Mar;22(3):332-339. doi: 10.1016/j.jval.2018.10.005. Epub 2018 Dec 14.
7
Prospective value-based assessment of new health care technologies and practices.新医疗技术和实践的前瞻性价值评估。
Manag Care. 2000 Aug;9(8):38-40, 43-7.
8
Pharmaceutical research: cost savings through innovation.药物研究：通过创新实现成本节约。
AAPPO J. 1993 Oct;3(5):28-36.
9
Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.药品价格与性价比：澳大利亚药品福利计划
JAMA. 2005 Nov 23;294(20):2630-2. doi: 10.1001/jama.294.20.2630.
10
Can technology truly reduce healthcare costs?
IEEE Eng Med Biol Mag. 2003 Jan-Feb;22(1):20-5. doi: 10.1109/memb.2003.1191445.

引用本文的文献

1
Estimating Productivity Loss from Breast and Non-Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method.估算工作年龄患者及无薪照护者中乳腺癌和非小细胞肺癌导致的生产力损失：一项使用乘数法的调查研究
MDM Policy Pract. 2022 Aug 3;7(2):23814683221113846. doi: 10.1177/23814683221113846. eCollection 2022 Jul-Dec.
2
Systematic Review of Cost-Effectiveness Analyses Comparing Open and Minimally Invasive Lumbar Spinal Surgery.比较开放和微创腰椎手术的成本效益分析的系统评价
Int J Spine Surg. 2022 Jul 14;16(4):612-24. doi: 10.14444/8297.
3
Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.

本文引用的文献

1
Measuring the Value of Prescription Drugs.衡量处方药的价值。
N Engl J Med. 2015 Dec 31;373(27):2595-7. doi: 10.1056/NEJMp1512009. Epub 2015 Nov 18.
利益相关者对ICER证据报告草案公众意见的参与情况分析。
Am Health Drug Benefits. 2020 Sep;13(4):136-142.
4
Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study.在阿片类药物流行期间，联邦合格健康中心的丙型肝炎管理：成本效益研究。
Am J Med. 2020 Nov;133(11):e641-e658. doi: 10.1016/j.amjmed.2020.05.029. Epub 2020 Jun 27.
5
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.1995 年至 2017 年间新批准的癌症疗法的中位和平均生命年获益的价格趋势。
Value Health. 2019 Dec;22(12):1387-1395. doi: 10.1016/j.jval.2019.08.005. Epub 2019 Sep 23.
6
Economic value of protected areas via visitor mental health.通过游客心理健康评估保护区的经济价值。
Nat Commun. 2019 Nov 12;10(1):5005. doi: 10.1038/s41467-019-12631-6.
7
Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016.2010-2016 年美国私人保险囊性纤维化患者的医疗保健支出。
Pediatr Pulmonol. 2018 Dec;53(12):1611-1618. doi: 10.1002/ppul.24178. Epub 2018 Oct 31.
8
Is ICER NICEr?增量成本效果比更合理吗？
Pharmacoeconomics. 2018 Apr;36(4):385-386. doi: 10.1007/s40273-018-0617-6.
9
Cost and Cost-Effectiveness Assessments of Newborn Screening for Critical Congenital Heart Disease Using Pulse Oximetry: A Review.使用脉搏血氧饱和度仪对危重型先天性心脏病进行新生儿筛查的成本及成本效益评估：一项综述
Int J Neonatal Screen. 2017;3(4):34. doi: 10.3390/ijns3040034. Epub 2017 Dec 14.